Iris LoewFriedrich - Evotec SE Member of the Supervisory Board
| EVOTF Stock | USD 13.83 0.00 0.00% |
Executive
Prof. Dr. Iris LoewFriedrich was Independent Member of the Supervisory Board at Evotec AG since June 17, 2014. She is Member of the Audit Committee at the Company. Since March 2008, she was serving as Chief Medical Officer and Executive Vice President responsible for Development at the Executive Committee of UCB S.A., Brussels, Belgium. From 2001 to 2009, she was Member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen. From 1992 to 2000, she held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion RousselAventis, Bridgewater, NJ, USA. Prof since 2014.
| Age | 57 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 49 40 560 81 0 |
| Web | https://www.evotec.com |
Evotec SE Management Efficiency
Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Eva Jack | Mersana Therapeutics | 49 | |
| Dawn FitzgeraldWilliams | Home Federal Bancorp | N/A | |
| Pilar Sanchez | Betterware De Mexico | N/A | |
| Jean Kim | Provident Bancorp | 50 | |
| Donald Bergstrom | Mersana Therapeutics | N/A | |
| MSc BBA | Immutep Ltd ADR | N/A | |
| Gerald Garrett | Marker Therapeutics | N/A | |
| Patricia Allison | Marker Therapeutics | N/A | |
| Donna Lewis | Home Federal Bancorp | 61 | |
| Edmund Cheung | Marker Therapeutics | N/A | |
| Nadia Agopyan | Marker Therapeutics | N/A | |
| Kenneth Fisher | Provident Bancorp | N/A | |
| Janine Jakubauskas | Provident Bancorp | N/A | |
| Mohan Bala | Mersana Therapeutics | N/A | |
| Kimberly Scholtz | Provident Bancorp | N/A | |
| Juan Hernandez | Betterware De Mexico | N/A | |
| Frederic Triebel | Immutep Ltd ADR | 60 | |
| Tushar Misra | Mersana Therapeutics | 63 | |
| Marc Damelin | Mersana Therapeutics | N/A | |
| Alejandro Miranda | Betterware De Mexico | N/A | |
| Mauricio Alvarez | Betterware De Mexico | 54 | |
Management Performance
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0012 |
Evotec SE Leadership Team
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Evers, Chief Board | ||
| Werner Lanthaler, President of the Management Board, CEO | ||
| Claus Braestrup, Member of the Supervisory Board | ||
| Michael Shalmi, Member of the Supervisory Board | ||
| Monika Conradt, Global HR | ||
| Christian Dargel, EVP Compliance | ||
| Mario Polywka, COO and Member of Management Board | ||
| Anja Bosler, Principal Accounting | ||
| Mary Tanner, Member of the Supervisory Board | ||
| Volker Braun, VP ESG | ||
| Roland Oetker, Deputy Chairman of the Supervisory Board | ||
| Andreas Pinkwart, Member of the Supervisory Board | ||
| Paul Herrling, Member of the Supervisory Board | ||
| Colin Bond, CFO and Member of Management Board | ||
| Cord Dohrmann, Chief Scientific Officer and Member of Management Board | ||
| Iris LoewFriedrich, Member of the Supervisory Board | ||
| Bernd Hirsch, Member of the Supervisory Board | ||
| Enno Spillner, CFO, Member of the Management Board | ||
| Elaine Sullivan, Member of the Supervisory Board | ||
| Gabriele Hansen, Vice President Corporate Communications & Investor Relations | ||
| MBA MBA, Chairman CEO | ||
| Craig Johnstone, COO, Member of the Management Board | ||
| Wolfgang Plischke, Chairman of the Supervisory Board |
Evotec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0012 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 2.68 B | |||
| Shares Outstanding | 176.95 M | |||
| Shares Owned By Insiders | 9.86 % | |||
| Shares Owned By Institutions | 66.12 % | |||
| Price To Earning | 347.66 X | |||
| Price To Book | 2.28 X |
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving against Evotec Pink Sheet
| 0.79 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.75 | TEVA | Teva Pharmaceutical | PairCorr |
| 0.52 | MKGAF | MERCK Kommanditgesells | PairCorr |
| 0.52 | AISP | Airship AI Holdings Symbol Change | PairCorr |
| 0.45 | MKKGY | Merck KGaA ADR | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Evotec Pink Sheet analysis
When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |